Patents by Inventor Harry Fisch

Harry Fisch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10758500
    Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: September 1, 2020
    Assignee: ASPEN PARK PHARMACEUTICALS, INC.
    Inventors: Mitchell Steiner, Harry Fisch
  • Publication number: 20200085768
    Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/ or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/ or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 24, 2019
    Publication date: March 19, 2020
    Applicant: ASPEN PARK PHARMACEUTICALS , INC.
    Inventors: MITCHELL STEINER, HARRY FISCH
  • Patent number: 10463635
    Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: November 5, 2019
    Assignee: ASPEN PARK PHARMACEUTICALS, INC.
    Inventors: Mitchell Steiner, Harry Fisch
  • Publication number: 20190054044
    Abstract: The present invention relates to a pharmaceutical oral dosage form comprising both (A) trans-clomiphene or a pharmaceutically acceptable salt thereof and (B) cis-clomiphene or a pharmaceutically acceptable salt thereof, wherein (i) the ratio of (A):(B) in the dosage form is about 70:30; (ii) the amount of (A) in the dosage form is about 12.5 mg or about 25 mg; and (iii) the amount of (B) in the dosage form is less than 15 mg. The pharmaceutical oral dosage form is useful to treat secondary hypogonadism in men and minimize certain antiestrogenic drug side effects such as impaired cognition, hot flashes and bone loss, osteoporosis, and skeletal fractures.
    Type: Application
    Filed: February 23, 2017
    Publication date: February 21, 2019
    Applicant: ASPEN PARK PHARMACEUTICALS, INC.
    Inventors: Mitchell Steiner, Harry Fisch
  • Publication number: 20190046465
    Abstract: The present invention relates to a sealed package containing one wipe, wherein the one wipe comprises a carrier and an active ingredient impregnated therein, wherein the active ingredient is selected from the group consisting of penile desensitizing agents. The sealed package can be opened, the wipe removed and wiped on the penis of a male to reduce the occurrence of premature ejaculation during subsequent intercourse. Repeated use of the wipes over time can result in statistically significant improvement in intravaginal ejaculatory latency time (IELT).
    Type: Application
    Filed: May 10, 2018
    Publication date: February 14, 2019
    Applicant: ASPEN PARK PHARMACEUTICALS, INC.
    Inventor: HARRY FISCH
  • Publication number: 20180153829
    Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 25, 2018
    Publication date: June 7, 2018
    Applicant: ASPEN PARK PHARMACEUTICALS, INC.
    Inventors: MITCHELL STEINER, Harry Fisch
  • Patent number: 9913815
    Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: March 13, 2018
    Assignee: ASPEN PARK PHARMACEUTICALS, INC.
    Inventors: Mitchell Steiner, Harry Fisch
  • Publication number: 20170202788
    Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 23, 2015
    Publication date: July 20, 2017
    Applicant: ASPEN PARK PHARMACEUTICALS , INC.
    Inventors: MITCHELL STEINER, HARRY FISCH
  • Publication number: 20160346223
    Abstract: The present invention relates to a sealed package containing one wipe, wherein the one wipe comprises a carrier and an active ingredient impregnated therein, wherein the active ingredient is selected from the group consisting of penile desensitizing agents. The sealed package can be opened, the wipe removed and wiped on the penis of a male to reduce the occurrence of premature ejaculation during subsequent intercourse.
    Type: Application
    Filed: January 20, 2015
    Publication date: December 1, 2016
    Applicant: Aspen Park Pharmaceuticals
    Inventor: HARRY FISCH
  • Publication number: 20110118355
    Abstract: A method of preventing or reducing the frequency of the occurrence of migraine headaches in a patient who is a previous sufferer of migraine headaches, especially accompanied by prodrome and/or aura, comprises administering an effective amount therefor of an antiestrogen to the patient for a period of time and sufficiently far in advance of the occurrence of a migraine headache to prevent the development of the prodromal phase and/or aura phase of the migraine headache.
    Type: Application
    Filed: September 20, 2010
    Publication date: May 19, 2011
    Inventor: Harry FISCH
  • Publication number: 20090105348
    Abstract: A method of preventing the occurrence of migraine headaches in a patient who is a previous sufferer of migraine headaches, especially accompanied by prodrome and/or aura, comprises administering an effective amount therefor of an antiestrogen to the patient for a period of time and sufficiently far in advance of the occurrence of a migraine headache to prevent the development of the prodromal phase and/or aura phase of the migraine headache.
    Type: Application
    Filed: October 17, 2008
    Publication date: April 23, 2009
    Inventor: HARRY FISCH
  • Publication number: 20090082467
    Abstract: A method of preventing the occurrence of migraine headaches in a patient who is a previous sufferer of migraine headaches comprises administering an effective amount therefor of an antiestrogen to the patient for a period of time and sufficiently far in advance of the occurrence of a migraine headache to prevent the development of the prodromal phase of the migraine headache.
    Type: Application
    Filed: September 19, 2008
    Publication date: March 26, 2009
    Inventor: Harry FISCH
  • Publication number: 20080014645
    Abstract: A method for reducing an antigen indicator of prostate cancer and for reducing the need for biopsies in men suspected of having prostate cancer and a method for treating patients with elevated PSA levels. In one method, the level of an antigen indicator of prostate cancer is measured and for an above normal level of the antigen indicator, an effective amount of an anti-inflammatory, or a combination of the anti-inflammatory and an antibiotic, is administered and the level of the antigen indicator is remeasured to determine if the level is normal or reduced, whereby a biopsy may not be indicated.
    Type: Application
    Filed: September 21, 2007
    Publication date: January 17, 2008
    Inventor: HARRY FISCH
  • Publication number: 20080009468
    Abstract: A method for reducing an antigen indicator of prostate cancer and for reducing the need for biopsies in men suspected of having prostate cancer and a method for treating patients with elevated PSA levels. In one method, the level of an antigen indicator of prostate cancer is measured and for an above normal level of the antigen indicator, an effective amount of an anti-inflammatory, or a combination of the anti-inflammatory and an antibiotic, is administered and the level of the antigen indicator is remeasured to determine if the level is normal or reduced, whereby a biopsy may not be indicated.
    Type: Application
    Filed: September 21, 2007
    Publication date: January 10, 2008
    Inventor: HARRY FISCH
  • Patent number: D569990
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: May 27, 2008
    Assignee: Millennium Sciences
    Inventor: Harry Fisch
  • Patent number: D874019
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: January 28, 2020
    Inventor: Harry Fisch
  • Patent number: D876666
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: February 25, 2020
    Inventor: Harry Fisch
  • Patent number: D879996
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: March 31, 2020
    Inventor: Harry Fisch
  • Patent number: D879997
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: March 31, 2020
    Inventor: Harry Fisch
  • Patent number: D879998
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: March 31, 2020
    Inventor: Harry Fisch